Gitali Bhagawati

Gitali Bhagawati


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2023 in Vaccines
Verified
Journal Article
Open access
PDF file
SJSarita Rani Jaiswal
Sarita Rani Jaiswal
ASAshraf Saifullah
Ashraf Saifullah
JAJaganath Arunachalam
Jaganath Arunachalam
RLRohit Lakhchaura
Rohit Lakhchaura
DTDhanir Tailor
Dhanir Tailor
SCSuparno Chakrabarti
Suparno Chakrabarti
Mycobacterium-w (Mw) was shown to boost adaptive natural killer (ANK) cells and protect against COVID-19 during the first wave of the pandemic. As a follow-up of the trial, 50 healthcare workers (HCW) who had received Mw in September 2020 and subsequently received at least one dose of ChAdOx1 nCoV-19 vaccine (Mw + ChAdOx1 group) were monitored for symptomatic COVID-19 during a major outbreak with the delta variant of SARS-CoV-2 (April–June 2021), along with 201 HCW receiving both doses of the vaccine without Mw (ChAdOx1 group). Despite 48% having received just a single dose of the vaccine in the Mw + ChAdOx1 group, only two had mild COVID-19, compared to 36 infections in the ChAdOx1 group (HR-0.46, p = 0.009). Transcriptomic studies revealed an enhanced adaptive NK cell-dependent ADCC in the Mw + ChAdOx1 group, along with downregulation of the TLR2-MYD88 pathway and concomitant attenuation of downstream inflammatory pathways. This might have resulted in robust protection during the pandemic with the delta variant.

21 October 2020 in medRxiv
Verified
Preprint
Open access
PDF file
SJSarita Rani Jaiswal
Sarita Rani Jaiswal
AMAnupama Mehta
Anupama Mehta
GBGitali Bhagawati
Gitali Bhagawati
RLRohit Lakhchaura
Rohit Lakhchaura
HAHemamalini Aiyer
Hemamalini Aiyer
SCSuparno Chakrabarti
Suparno Chakrabarti
To evaluate ability of modulated innate immune response to provide resistance to development of symptomatic RT-PCR confirmed COVID-19, 96 inpatient front line health care workers (HCW) were cohorted in 1:2 ratio to receive TLR2 agonist (heat killed Mycobacterium w, Mw; n=32) as innate immune response modulator or observation (n=64). All were followed up for 100 days. The incidence of COVID-19 was 31 (32.3%) for the entire cohort, with only one developing COVID-19 in Mw group (3.1% vs 46.8%. protective efficacy - 93.33%, p=0.0001; 95% CI 53.3-99.1). Self-limiting local injection site reaction was the only side effect and was seen in 14 HCW. Findings from the study suggest the potential for providing resistance against novel pathogen like SARS-CoV-2 by modulating innate immune response.

1 March 2022 in Journal of Clinical and Diagnostic Research
Verified
Journal Article
Closed access
GBGitali Bhagawati
Gitali Bhagawati
SPSania Paul
Sania Paul
SJSarita Rani Jaiswal
Sarita Rani Jaiswal
ABAshutosh Bhardwaj
Ashutosh Bhardwaj
RKRekha Saji Kumar
Rekha Saji Kumar
SCSuparno Chakrabarti
Suparno Chakrabarti
Journal of Clinical and Diagnostic Research aims to publish findings of doctors at grass root level and post graduate students, so that all unique medical experiences are recorded in literature.